Allergy Therapeutics PLC AGY.L
GBX5.00 GBX0.25 (4.76%) 1D
Last Updated: Sep 07, 12:00 AM·LSE
Pricing for GB stocks is delayed by 24 hours
Open navigation menu
Invest
Invest on your own
We do it for you
Halal tools
Screeners
Your portfolio
Calculators
Shariah
Our certifications
Learn
Education
Get help
Pricing
Company
About Musaffa
Investors
Build with us
Is Allergy Therapeutics PLC Stock Halal?
Shariah Compliance Analysis of AGY.L Stock
United Kingdom Health Care Small Cap Yes. As of September 2026, Allergy Therapeutics PLC (AGY.L) is classified as HALAL by Musaffa under its AAOIFI-based Shariah screening methodology. Allergy Therapeutics PLC passes Musaffa's business and financial screening criteria.
Allergy Therapeutics Plc is a biotechnology company, which engages in the Research and Development of allergy treatments. The firm is focused on the treatment and diagnosis of allergic disorders, including aluminum free immunotherapies that have the potential to cure disease. The company sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional 10 countries. The company sells both injectable and sublingual (oral) allergen-specific immunotherapies. Its pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. Its therapies are traded under various brand names depending on the market, such as Pollinex Quattro, Polligoid and TA Graser Top. Its commercial products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics and Acarovac Plus. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL, and VLP Peanut.
AGY.L Shariah Compliance
Screening Methodology: AAOIFI
As of September 2026, Allergy Therapeutics PLC is classified as halal.
HALAL
Report Source: undefined Quarter Report
Allergy Therapeutics PLC (AGY.L) Chart
Financial Metrics & Statements of Allergy Therapeutics PLC (AGY.L)
FAQ's for Allergy Therapeutics PLC (AGY.L)
- As of September 2026, Allergy Therapeutics PLC AGY.L is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Allergy Therapeutics PLC using these criteria to determine its compliance status.
- Muslim investors may consider investing in Allergy Therapeutics PLC if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Allergy Therapeutics PLC by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Allergy Therapeutics PLC may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Allergy Therapeutics PLC on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Related Halal Stocks to Allergy Therapeutics PLC (AGY.L)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
